HQY HealthEquity Inc

Innovative Benefits Plan Demonstrates How HSAs can Further Pay Equity

Innovative Benefits Plan Demonstrates How HSAs can Further Pay Equity

By employing income-tiered HSA contributions, Pfizer increases enrollment and advances DEI initiatives

DRAPER, Utah, Dec. 13, 2022 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity”), the leader in health savings accounts (HSAs) and consumer-directed benefits administration today released the initial results of an innovative DEI benefits plan developed and executed with Pfizer.

The plan HealthEquity designed, categorizes employees into four separate income tiers and gives lower income earners the largest employer HSA contribution when they enroll. This incentivizes lower income earners to sign up and contribute to an HSA.  

For Michele Proscia, director of U.S. and Puerto Rico Health and Insurance Benefits team at Pfizer it was important to find a solution that benefited all employees.  

“We knew HSAs are attractive for our more highly paid colleagues looking for a tax savings vehicle. But we also wanted to support our lower paid colleagues, while still providing access to affordable, comprehensive healthcare coverage,” said Proscia. “From an enrollment perspective, it was a huge success.” 

According to Pfizer, the first-year plan increased participation with over one-third of their eligible colleagues enrolling in the HSA plan, including 37% of those in the lowest salary tier.  

“This is an incredible example of how benefits can drive DEI efforts,” said Kerry Clucas, Account Executive to Pfizer at HealthEquity. “Most benefit leaders agree that DEI is a priority for their company, yet they’re unsure how benefits can make a difference in this area.” 

In its October 2022 national employer survey, HealthEquity discovered 96% of employers view benefits as important to success for DEI yet only 45% believe their current benefits offering is having a positive impact on it. Additionally, the data revealed 1 in 4 HR leaders believe lower-wage earners are underserved by their organization’s benefits. HealthEquity’s and Pfizer’s partnership aims to pattern a successful approach to equitable benefit design.  

This plan seeks to help all employees—regardless of income—get the resources they need to manage healthcare and support their long-term financial wellbeing.  

To learn more about the partnership visit the  at:

To see the full research findings visit HealthEquity benefits equity page at:

About HealthEquity  

HealthEquity is the leading administrator of Health Savings Accounts (HSAs) and other consumer-directed benefits, serving more than 14 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit   

Media Contact 

Amy Cerny  

801-508-3237  

 



EN
13/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HealthEquity Inc

 PRESS RELEASE

HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Direc...

HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that William ‘Bill’ Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors (the “Board”) effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture ...

 PRESS RELEASE

HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales ...

HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook Highlights of the fiscal year include: Revenue increased 9% to $1.31 billion.Net income increased 123% to $215.2 million, and net income margin increased to 16% from 8% last year.Net income per diluted share rose to $2.46 from $1.09 one year ago, and non-GAAP net income per diluted share increased 28% to $4.00.Adjusted EBITDA increased 20% to $566.0 million, and Adjusted EBITDA margin increased to 43% from 39% last year.Total HSA ...

 PRESS RELEASE

HealthEquity Delivers Record Q4 and Standout Fiscal 2026 Sales Metrics

HealthEquity Delivers Record Q4 and Standout Fiscal 2026 Sales Metrics Announces earnings date and upcoming investor conferences DRAPER, Utah, Feb. 17, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation's largest health savings account (“HSA”) custodian by number of accounts and leading provider of complementary consumer-directed benefits (“CDBs”), today announced its HSAs, HSA Assets, and Total Accounts as of its fiscal year ended January 31, 2026. The Company also reaffirmed its guidance for fiscal 2026 and 2027, provided an updated...

 PRESS RELEASE

HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. M...

HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. Morgan Healthcare Conference DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian by number of accounts and leading provider of complimentary consumer-directed benefits (“CDBs”), today announced its initial outlook for its fiscal year ending January 31, 2027 and reaffirmed previously provided guidance for its fiscal year ending January 31, 2026. For the fiscal year ending January 31, 2027, managem...

Healthequity Inc: 2 directors

A director at Healthequity Inc sold 10,959 shares at 95.455USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch